RxDoctor Payments DataLook up a doctor →

Sara Horst, MD

Gastroenterology · Nashville, TNNPI 1265551295

Payments from drug & device makers

$1,189,449in general payments, 2019–2025

Across 539 payments — averaging $2206.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$811K
  • Boehringer Ingelheim$91K
  • Takeda Pharmaceuticals U.S.A., Inc.$89K
  • Eli Lilly$59K
  • Johnson & Johnson$30K
  • Pfizer$30K
  • plus $79K from 12 others
$13,358in research payments, 2019–2025

Across 4 payments — averaging $3339.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$9K
  • UCB, Inc.$5K

What the payments were for

  • Consulting fees$147,57360%
  • Speaking & faculty fees$25,08010%
  • Grants$50,00020%
  • Travel & lodging$14,5886%
  • Food & beverage$8,7444%
  • Education$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,189,449 in reported general payments places this provider in the 95th percentile of 336 gastroenterology providers in Tennessee.

See all gastroenterology providers in Tennessee

Medicare billing

Part B allowed, 2024
$21,645
Medicare patients
102
Services billed
191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab145$3,940,056
Skyrizi On-BodyRisankizumab-Rzaa35$678,414
Humira(Cf) PenAdalimumab27$318,893
Humira(Cf)Adalimumab25$240,920
XifaxanRifaximin11$25,500
Mesalamine18$14,680
Ciprofloxacin Hcl27$851
LoperamideLoperamide Hcl21$842
Omeprazole58$841
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine16$654
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl25$344
Metronidazole25$194
Ondansetron Hcl20$85
Metoclopramide Hcl11$69

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$30,153$3,940,056145 claims
AbbVieHumira(Cf)$810,663$240,92025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 336 gastroenterology providers in Tennessee.

Other gastroenterology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →